Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)
Cedarbaum JM, Silvestri M, Clark M, Toy L, Harts A, Green-Parsons A, McDowell FH. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR). Journal Of Neural Transmission: Parkinson's Disease A And Dementia Section 1990, 2: 205-213. PMID: 2257060, DOI: 10.1007/bf02257651.Peer-Reviewed Original ResearchConceptsStandard SinemetMotor response fluctuationsResponse fluctuationsSinemet CRDisease patientsControlled-release levodopa/carbidopaLevodopa/carbidopaLong-term treatmentParkinson's disease patientsLong-term managementAntiparkinson effectEligible patientsMost patientsMedication dosesInterdose intervalClinical trialsParkinson's diseaseUseful adjunctPatientsSinemetDiseaseYearsCarbidopaAdjunctDoseL-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease.
Cedarbaum JM, Silvestri M, Clark M, Harts A, Kutt H. L-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease. Clinical Neuropharmacology 1990, 13: 29. PMID: 2106391, DOI: 10.1097/00002826-199002000-00003.Peer-Reviewed Original ResearchConceptsParkinson's diseaseResponse fluctuationsL-deprenylTherapeutic response fluctuationsTotal levodopa doseOpen-label trialPlasma levodopa concentrationsPlasma levodopa levelsEffect of deprenylWeeks of treatmentDaily levodopaLevodopa doseLevodopa pharmacokineticsPeripheral pharmacokineticsAction of MAOLevodopa treatmentMost patientsDOPAC levelsLevodopa levelsDopaminergic activityLevodopa concentrationsMild endDose failureTherapeutic actionPatients